Back to Results

China Pharma Holdings Inc (CPHI)

China Pharma Holdings Inc. is a common stock listing on the NYSE for a healthcare company focused on pharmaceuticals. Based in Haikou, People’s Republic of China, the company develops, manufactures, and markets human pharmaceutical products for the domestic Chinese market. Its portfolio includes dry powder and liquid injectables, tablets, capsules, and cephalosporin oral solutions. The company’s products are used across a range of therapeutic areas, including neurological, cardiovascular, respiratory, anti-infective, digestive, and oncology-related supportive care applications. China Pharma also supplies items such as sanitizers, masks, and a food supplement. Its products are distributed to hospitals and over-the-counter pharmacies through provincial and municipal pharmaceutical logistics companies.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-CPHI
$0.43
-18.1% Downside
Overvalued
Not available
Not available
Weak
0.0%
November 12, 2026
0.6x
5.8x
22.802 M
26.553 M
15.3%
7.7%
-28.2
3.2%
Valuation • Fair Value

China Pharma Holdings Inc (NYSE-CPHI) Fair Value by Valuation Model

Review the available estimates for China Pharma Holdings Inc (NYSE-CPHI), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.43

Estimated downside of 18.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.44

Discounted cash flow valuation reference.

Comps Fair Value

$0.43

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for China Pharma Holdings Inc (NYSE-CPHI) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for China Pharma Holdings Inc (NYSE-CPHI)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

3.914 M

Current operating scale indicator.

Revenue Forecast

4.144 M

Forward revenue estimate.

EBITDA

-1.441 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review China Pharma Holdings Inc (NYSE-CPHI) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for China Pharma Holdings Inc (NYSE-CPHI)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-4.37

No elevated caution signal from this screen.

Altman Z-Score

-28.2

Lower score that deserves closer risk review.

FCF / Net Income

3.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for China Pharma Holdings Inc (NYSE-CPHI). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for China Pharma Holdings Inc (NYSE-CPHI)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

6

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for China Pharma Holdings Inc (NYSE-CPHI), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for China Pharma Holdings Inc (NYSE-CPHI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for China Pharma Holdings Inc (NYSE-CPHI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for China Pharma Holdings Inc (NYSE-CPHI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for China Pharma Holdings Inc (NYSE-CPHI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for China Pharma Holdings Inc (NYSE-CPHI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

China Pharma Holdings Inc (NYSE-CPHI) Stock FAQ

Data-supported answers about China Pharma Holdings Inc (NYSE-CPHI), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.43
Estimated downside 18.1%
Valuation Rating
Overvalued
Estimated downside of 18.1%
Financial Health
Weak
Current financial-health read

The current fair value estimate for China Pharma Holdings Inc (NYSE-CPHI) is $0.43. This implies an estimated downside of 18.1% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 18.1% versus the current market price.

The current financial health read for China Pharma Holdings Inc (NYSE-CPHI) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for China Pharma Holdings Inc (NYSE-CPHI) is November 12, 2026.

The latest available data indicates no current dividend yield for China Pharma Holdings Inc (NYSE-CPHI).

The current market capitalization listed for China Pharma Holdings Inc is 22.802 M.

The current enterprise value listed for China Pharma Holdings Inc is 26.553 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for China Pharma Holdings Inc is NYSE-CPHI, and the stock is listed on NYSE.

China Pharma Holdings Inc (NYSE-CPHI) is listed on NYSE.

The current debt-to-total-capital ratio listed for China Pharma Holdings Inc is 15.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for China Pharma Holdings Inc is 7.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NYSE

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,215.6 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 655.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.2 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 310 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 179.5 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 170.3 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 129 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 113.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 69.723 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 48.75 B
HLN NYSE HALEON PLC ADR Fair Value Undervalued Market Cap 40.368 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 38.751 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.93 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 21.789 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Undervalued Market Cap 14.59 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 11.996 B
ELAN NYSE Elanco Animal Health Fair Value Overvalued Market Cap 11.831 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 7.834 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 6.827 B